Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The company has 3 R&D and 5 manufacturing facilities.
52% turnover from International Generics #
Alembic Pharma operates through 3 primary business segments - International generics (52% of sales, with 75% being from the US), Domestic branded business (32% of sales), and API business(16% of sales) as of Q3FY21.
US Generics business has grown at a CAGR of 29% for last 4 years #
- Market Cap ₹ 18,025 Cr.
- Current Price ₹ 917
- High / Low ₹ 1,150 / 435
- Stock P/E 15.5
- Book Value ₹ 233
- Dividend Yield 0.76 %
- ROCE 24.2 %
- ROE 29.1 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 24.99% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 24.72%
- Company has been maintaining a healthy dividend payout of 19.59%
Cons
- No cons found. Suggest something.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
853 | 863 | 1,127 | 1,018 | 927 | 949 | 1,241 | 1,209 | 1,207 | 1,341 | 1,457 | 1,314 | |
680 | 712 | 825 | 776 | 749 | 724 | 895 | 884 | 915 | 934 | 1,014 | 949 | |
Operating Profit | 173 | 151 | 302 | 242 | 178 | 225 | 346 | 325 | 292 | 407 | 443 | 365 |
OPM % | 20% | 18% | 27% | 24% | 19% | 24% | 28% | 27% | 24% | 30% | 30% | 28% |
Other Income | 1 | 0 | 2 | 4 | 3 | -30 | 0 | 0 | 25 | 0 | 3 | 3 |
Interest | 1 | 2 | 6 | 6 | 5 | 5 | 7 | 7 | 8 | 7 | 4 | 2 |
Depreciation | 32 | 28 | 29 | 29 | 30 | 35 | 36 | 42 | 44 | 42 | 44 | 47 |
Profit before tax | 141 | 122 | 270 | 211 | 146 | 155 | 303 | 276 | 266 | 360 | 398 | 318 |
Tax % | 27% | 26% | 26% | 19% | 10% | 23% | 17% | 18% | 23% | 19% | 18% | 19% |
Net Profit | 94 | 90 | 200 | 170 | 124 | 124 | 246 | 234 | 225 | 301 | 333 | 293 |
EPS in Rs | 4.98 | 4.80 | 10.61 | 9.01 | 6.58 | 6.56 | 13.06 | 12.42 | 11.93 | 15.99 | 16.96 | 14.88 |
Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|
1,202 | 1,465 | 1,520 | 1,863 | 2,056 | 3,166 | 3,105 | 3,131 | 3,935 | 4,606 | 5,320 | |
1,042 | 1,246 | 1,268 | 1,506 | 1,653 | 2,159 | 2,489 | 2,488 | 3,061 | 3,385 | 3,812 | |
Operating Profit | 160 | 219 | 252 | 358 | 403 | 1,007 | 616 | 643 | 874 | 1,221 | 1,508 |
OPM % | 13% | 15% | 17% | 19% | 20% | 32% | 20% | 21% | 22% | 27% | 28% |
Other Income | 4 | 13 | 4 | 4 | 4 | 7 | 1 | 7 | 9 | -37 | 32 |
Interest | 28 | 38 | 15 | 10 | 4 | 5 | 5 | 3 | 18 | 27 | 21 |
Depreciation | 30 | 34 | 35 | 40 | 44 | 72 | 83 | 105 | 115 | 157 | 176 |
Profit before tax | 107 | 161 | 206 | 311 | 359 | 936 | 529 | 541 | 749 | 1,000 | 1,342 |
Tax % | 20% | 19% | 20% | 24% | 21% | 23% | 23% | 22% | 21% | 20% | |
Net Profit | 85 | 130 | 165 | 236 | 283 | 720 | 403 | 413 | 584 | 829 | 1,152 |
EPS in Rs | 6.90 | 8.77 | 12.49 | 15.01 | 38.20 | 21.39 | 21.89 | 31.00 | 43.97 | 59.76 | |
Dividend Payout % | 6% | 20% | 29% | 24% | 23% | 9% | 19% | 18% | 18% | 23% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 18% |
3 Years: | 14% |
TTM: | 23% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 25% |
3 Years: | 29% |
TTM: | 54% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 19% |
1 Year: | 47% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 28% |
3 Years: | 25% |
Last Year: | 29% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Sep 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|
38 | 38 | 38 | 38 | 38 | 38 | 38 | 38 | 38 | 38 | 39 | |
Reserves | 259 | 357 | 465 | 638 | 847 | 1,560 | 1,865 | 2,182 | 2,681 | 3,182 | 4,540 |
Borrowings | 328 | 353 | 187 | 109 | 264 | 114 | 89 | 708 | 1,128 | 1,747 | 600 |
246 | 304 | 358 | 432 | 493 | 718 | 698 | 1,013 | 931 | 1,022 | 1,156 | |
Total Liabilities | 844 | 1,052 | 1,048 | 1,217 | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,336 |
272 | 268 | 344 | 397 | 547 | 708 | 799 | 993 | 1,158 | 1,552 | 1,815 | |
CWIP | 26 | 58 | 32 | 21 | 83 | 93 | 396 | 1,010 | 1,551 | 1,846 | 1,830 |
Investments | 3 | 3 | 3 | 3 | 2 | 87 | 50 | 42 | 49 | 18 | 18 |
542 | 723 | 668 | 796 | 1,009 | 1,541 | 1,444 | 1,896 | 2,019 | 2,573 | 2,674 | |
Total Assets | 844 | 1,052 | 1,048 | 1,217 | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,336 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|
95 | 142 | 265 | 240 | 172 | 948 | 329 | 312 | 812 | 449 | |
-57 | -56 | -67 | -81 | -256 | -307 | -486 | -884 | -756 | -731 | |
-47 | -45 | -229 | -151 | 87 | -224 | -129 | 503 | 59 | 155 | |
Net Cash Flow | -9 | 41 | -31 | 8 | 3 | 417 | -286 | -69 | 115 | -127 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|
ROCE % | 29% | 31% | 44% | 38% | 66% | 29% | 22% | 23% | 24% | |
Debtor Days | 61 | 50 | 56 | 54 | 64 | 40 | 40 | 61 | 45 | 69 |
Inventory Turnover | 3.09 | 2.69 | 2.58 | 2.19 | 1.76 | 1.53 | 1.40 | 1.27 | 1.06 |
Documents
Add documentRecent announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 13h
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 1d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 2d
- Announcement under Regulation 30 (LODR)-Newspaper Publication 23 Feb
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 18 Feb
View all
Annual reports
- Financial Year 2020 from bse
- Financial Year 2019 from bse
- Financial Year 2018 from bse
- Financial Year 2017 from bse
- Financial Year 2016 from bse
- Financial Year 2015 from bse
- Financial Year 2014 from bse
- Financial Year 2013 from bse
- Financial Year 2012 from bse
- Financial Year 2012 from nse
- Financial Year 2011 from bse